June 12th 2025, 9:00pm
By Patti McGee
Joining support groups after cancer treatment helped me heal emotionally, connect with others who understood and embrace a new, meaningful normal.
June 12th 2025, 8:00pm
By Dr. Joshua K. Sabari
Expert oncologists Dr. Joshua K. Sabari and Dr. Eric K. Singhi break down key updates and takeaways in lung cancer treatment following ASCO 2025.
June 12th 2025, 7:00pm
By Glenna Sears-Brinker
Facing two life-threatening diagnoses, I overcame fear of self-injections by leaning on love, encouragement and determination to save my life.
June 12th 2025, 6:11pm
By Bridget Hoyt
The FDA has granted approval to UGN-102 for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.
June 12th 2025, 5:00pm
By Georgia Hurst
Eminem’s lyric about having “one shot” stayed with me, and writing this letter to my newly diagnosed self, reminds me how that mindset saved my life.
June 12th 2025, 4:00pm
By Ryan Scott
Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.
June 12th 2025, 3:00pm
By Spencer Feldman
FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as capsules.
June 12th 2025, 1:00pm
By Dr. Michael Serzan
Dr. Michael Serzan provides expert takeaways on treatment updates for patients with early-stage kidney cancer following the 2025 ASCO Meeting.
June 11th 2025, 9:00pm
By Kelly Irvin
Being a cancer survivor for nine and a half years has taught me to live in the moment, to make those moments count.
June 11th 2025, 8:00pm
Dr. Joshua K. Sabari sat down with Dr. Daniel V. Araujo to discuss topline takeaways from the 2025 ASCO Meeting across the realm of genitourinary oncology
June 11th 2025, 5:40pm
The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
June 11th 2025, 5:00pm
By Diana M. Martin
Two people connect by sharing their experiences about taking care of their spouses who died from cancer, and the realization that sparked something more.
June 11th 2025, 4:30pm
Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.
June 11th 2025, 3:00pm
FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.
June 11th 2025, 1:00pm
By Michelle Kirschner
Patients can prepare for self-advocacy by bringing personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner.
Revolutionizing CAR T-Cell Therapy to Improve Patient Access
Understanding Financial Toxicity and Navigating the System During Cancer
What Is Immunotherapy-Induced Diabetes?
Breaking Down Every FDA Approval Across Oncology During July 2025